论文部分内容阅读
目的分析了派罗欣联合利巴韦林在慢性丙肝治疗中的疗效和安全性。方法我院于2009年到2011年共收治慢性丙型肝炎患者200例,200例患者按照分层随机分组法随机分为两组,对照组和治疗组,每组患者100例,对照组采用干扰素和利巴韦林进行治疗,治疗组采用派罗欣联合利巴韦林进行治疗,治疗12个月后对治疗效果以及安全性进行评估。结果与对照组相比较,治疗组患者在早期应答、完全应答率、部分应答率以及无效率等指标具有显著性改变,具有统计学意义(P<0.05)。结论派罗欣联合利巴韦林治疗慢性丙型肝炎疗效显著,而且药物使用方便,值得临床推广使用。
Objective To analyze the efficacy and safety of Pegasys combined with ribavirin in the treatment of chronic hepatitis C. Methods A total of 200 patients with chronic hepatitis C were treated in our hospital from 2009 to 2011. 200 patients were randomly divided into two groups according to the stratified randomization method: control group and treatment group, with 100 patients in each group. The control group was treated with interference Su and ribavirin treatment, the treatment group with Pegasys combined with ribavirin treatment, treatment of 12 months after the treatment effect and safety assessment. Results Compared with the control group, the patients in the treatment group had significant changes in early response, complete response rate, partial response rate and inefficiency, with statistical significance (P <0.05). Conclusion Pegasys combined with ribavirin has significant curative effect on chronic hepatitis C, and the drug is convenient to use, which is worthy of clinical promotion.